• Disclaimer
• SiteMap
• Home

• about us
  • Corporate Profile
  • Board of Directors
• technology
  • GIPET®
  • Strategic Partnering
• portfolio
  • Product Pipeline
  • Strategic Partnering
  • Orazol™ (Breast Cancer)
  • Orazol™ (Bone Metastases)
  • Almerol™ (MER-103)
  • Acyline (MER-104)
  • MER-102
• investor relations
  • Corporate Profile
  • Share Information
  • Annual Reports /
    Financial Information
  • Financial Calendar
  • Investor Alert
  • Regulatory News
  • Corporate Governance
  • Analyst Coverage
  • Advisors and Registrars
  • Ownership Summary
  • Rule 26 Information
• media
• contact

Press Releases / Publications

• Print page
• Email page

Some of the articles are in PDF format. You will need Adobe Acrobat Reader to view them. Click on the logo to download it for free.

2013	2012	2011	2010	2009	2008	2007	2006/04

2013

Mar 13

Novo Nordisk A/S Successfully Completes Phase I Trial of its Proprietary Oral Insulin (NN1954) Using Merrion Pharmaceuticals GIPET® Technology